The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?
Featured:
Doris HansenDuring the 2022 ASCO Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Doris Hansen, Moffitt Cancer Center, Tampa, US. We asked, Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?
Is experience with ide-cel CAR-T in the real-world setting comparable to the KarMMa trial results?
In this video, Hansen discusses real-world data, including safety and progression-free survival data, compared with results from the KarMMa trial.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
